FDA Approves Phase 2 Trial for Promising New Drug AK3280 to Treat Pulmonary Fibrosis Shanghai Ark Biopharmaceutical's AK3280 has received FDA approval for Phase 2 trials, promising new hope for idiopathic pulmonary fibrosis patients. Explore the potential impact.

FDA Approves Phase 2 Trial for Promising New Drug AK3280 to Treat Pulmonary Fibrosis #Shanghai #United_States #FDA_Approval #AK3280 #Ark_Biopharmaceutical

Ark Biopharmaceutical's Aizhida Approved in China for ADHD Treatment Ark Biopharmaceutical's new ADHD medication, Aizhida, has been approved in China, offering a unique dual mechanism for effective symptom control.

Ark Biopharmaceutical's Aizhida Approved in China for ADHD Treatment #China #Shanghai #ADHD #Ark_Biopharmaceutical #Aizhida

Ark Biopharmaceutical Gains Approval for Azstarys® to Treat ADHD in China Ark Biopharmaceutical has achieved a significant milestone with the approval of Azstarys® by China's NMPA for ADHD treatment, marking a vital new option for patients.

Ark Biopharmaceutical Gains Approval for Azstarys® to Treat ADHD in China #China #Shanghai #Azstarys #ADHD_treatment #Ark_Biopharmaceutical